Sofosbuvir-velpatasvir-voxilaprevir provides salvage therapy for NS5A failures
Mark Fuerst
Advertisement
Articles by Mark Fuerst
Despite the availability of new, highly successful direct-acting antiviral (DAA) regimens, more than one third of chronic hepatitis C (HCV) patients are denied access to treatment by their insurance provider, according to a new study.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Medical Economics
1
Why Medicare’s 20% modifier 25 cut still penalizes same-day care
2
2027 Medicare Physician Fee Schedule: internal medicine, medical groups and telehealth advocates respond
3
Fewer hands, more patients: Clinic support staff shrinks as provider workloads climb
4
Primary care is still underpaid and federal policy could make access worse: report
5